NCT06234306 Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
| NCT ID | NCT06234306 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Copenhagen University Hospital at Herlev |
| Condition | Small Bowel Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-01-01 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.
Eligibility Criteria
Inclusion criteria: Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years Exclusion criteria: Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\& Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.
Contact & Investigator
Dan Høgdall, MD PhD
PRINCIPAL INVESTIGATOR
Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte
Frequently Asked Questions
Who can join the NCT06234306 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small Bowel Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06234306 currently recruiting?
Yes, NCT06234306 is actively recruiting participants. Contact the research team at danhog01@regionh.dk for enrollment information.
Where is the NCT06234306 trial being conducted?
This trial is being conducted at Aarhus N, Denmark, Copenhagen Ø, Denmark, Herlev, Denmark.
Who is sponsoring the NCT06234306 clinical trial?
NCT06234306 is sponsored by Copenhagen University Hospital at Herlev. The principal investigator is Dan Høgdall, MD PhD at Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte. The trial plans to enroll 500 participants.